GUIDANCE ONNOCLINCAL SAFETY STUDIES FOR THE CONDUCT OFHUMAN CLINCAL TRIALS AND MARKETING AUTHORIZATI

This guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties .In accordance with the ICH Process . At Step 4 of the Process the draft is recommended for adoption to the regulatory bodies of the European Union , Japan and the USA .